Oculis (NASDAQ:OCS) Shares Gap Up – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS)’s share price gapped up before the market opened on Monday . The stock had previously closed at $23.07, but opened at $24.33. Oculis shares last traded at $23.7550, with a volume of 42,265 shares traded.

Wall Street Analyst Weigh In

Several equities analysts have commented on OCS shares. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. HC Wainwright raised their price target on Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Bank of America cut their target price on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Wednesday, October 8th. Finally, Lifesci Capital initiated coverage on Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

Oculis Trading Up 2.7%

The business has a 50-day simple moving average of $20.07 and a two-hundred day simple moving average of $19.02. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -9.39 and a beta of 0.31.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. The firm had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. Equities analysts forecast that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its position in Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after buying an additional 878 shares in the last quarter. Aventura Private Wealth LLC bought a new stake in shares of Oculis during the 4th quarter valued at approximately $80,000. Geode Capital Management LLC grew its stake in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after buying an additional 6,384 shares during the last quarter. Compagnie Lombard Odier SCmA raised its position in Oculis by 11.5% in the second quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock valued at $1,883,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Bosun Asset Management LLC bought a new position in Oculis in the 2nd quarter valued at approximately $378,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.